ACAD - ACADIA Pharmaceuticals Inc.

ACAD Stock Chart

ACAD Profile

ACADIA Pharmaceuticals Inc., a prominent biopharmaceutical firm, specializes in pioneering and commercializing innovative treatments aimed at addressing critical unmet needs in central nervous system (CNS) disorders and rare diseases. One of its notable offerings includes NUPLAZID (pimavanserin), a medication approved for managing hallucinations and delusions associated with Parkinson's disease psychosis. The company's robust pipeline features Trofinetide, a synthetic analog of insulin-like growth factor 1's amino-terminal tripeptide, currently under development for treating Rett Syndrome. ACADIA Pharmaceuticals is also advancing Pimavanserin through Phase III trials for addressing the negative symptoms of schizophrenia, alongside developing ACP-204 targeting Alzheimer's disease psychosis and various antisense oligonucleotide programs.

In addition to its internal developments, ACADIA Pharmaceuticals maintains strategic partnerships to broaden its therapeutic capabilities. These include a licensing agreement with Neuren Pharmaceuticals Limited to co-develop and commercialize Trofinetide for Rett syndrome and other potential indications. Moreover, a collaboration with Stoke Therapeutics, Inc. focuses on the discovery and development of RNA-based therapies targeting severe and rare genetic neurodevelopmental CNS disorders. Founded in 1993 as Receptor Technologies, Inc. and rebranded as ACADIA Pharmaceuticals Inc. in 1997, the company is headquartered in San Diego, California, where it continues to innovate and advance treatments that aim to improve the lives of patients worldwide.

Driven by a commitment to scientific excellence and patient care, ACADIA Pharmaceuticals remains at the forefront of CNS disorder research. By leveraging its deep understanding of neurological diseases, the company strives to deliver breakthrough therapies that address complex medical challenges. With a dedication to innovation and strategic partnerships, ACADIA Pharmaceuticals is poised to shape the future of treatment options for CNS disorders and rare diseases, reinforcing its position as a leader in biopharmaceutical innovation.

ACAD Revenue Chart

ACAD Earnings

Analyst Ratings